Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) announced the recruitment of Ton Berkien as Chief Business Officer effective October 1.
Mr. Berkien joins the management team at Cantargia with approximately 30 years of experience in pharma, biotech, investment, and consulting complemented by significant experience in business development.
In a statement, Göran Forsberg, CEO of Cantargia, said that the company has made significant progress in the nadunolimab and CAN10 clinical programs, forming the base for next steps in business development efforts. “I am extremely pleased that Ton has decided to join Cantargia to take responsibility of and strengthen our business development activities.”
Most recently, Mr. Berkien was Chief Business Officer at Ultimovacs and has held senior business development positions at Amgen, Nuevolution, Takeda, and Nycomed.
